About: TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 29 October 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) artículu científicu espublizáu n'ochobre de 2019 (ast) scientific article published on 29 October 2019 (en) наукова стаття, опублікована 29 жовтня 2019 (uk)
publication date	wds:Q90990173-697DCD5B-F925-44FC-985B-24E9082FA85D
publication date	2019-10-29 00:00:00Z (xsd:dateTime)
author name string	wds:Q90990173-0274A082-DEF3-4CE7-8A0D-62FEE17373D7 wds:Q90990173-5DCD4298-9D10-4728-A2CA-AF7A556597EC wds:Q90990173-67744DBC-34D9-47AA-B69C-B2739434358B wds:Q90990173-69614504-24B0-4287-BDA5-52E262E05822 wds:Q90990173-7832D7B4-9A6E-4BF7-AEF2-A6F607C0D001 wds:Q90990173-8DBDBFD0-C8EB-41FE-8E91-4AAA00C0F2E6 wds:Q90990173-94C4222B-BAF1-4333-B0F9-C87629BE0079 wds:Q90990173-9DE53C80-37AC-4BF2-BAFD-3CC94757FD39 wds:Q90990173-A0F2E25C-5AA4-4ADC-AAD3-2805A7BA2AA3 wds:Q90990173-B885E732-60AB-45F4-84C6-78B93D3F9F8F wds:Q90990173-C8211DD3-09B6-4FE8-A29F-548705240793 wds:Q90990173-DCBB76F4-F1A3-4407-BCCA-56DA05CE93E8 wds:Q90990173-EA740820-2D1C-48E9-AC48-B4EA6804C907 wds:Q90990173-FAA66899-3F44-41C1-B8AB-13952E8DEC84
author name string	C Kent Osborne Carolina Gutierrez Mothaffar F Rimawi Ian Krop Andres Forero Rita Nanda Jamunarani Veeraraghavan Polly Niravath Anne Pavlick Sao Jiralerspong Brent N Rexer Carmine De Angelis Translational Breast Cancer Research Consortium Julie R Nangia
rdfs:label	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer (en) TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer (nl)
skos:prefLabel	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer (en) TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer (nl)
name	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer (en) TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer (nl)
author	wds:Q90990173-5FE6B85A-4447-421C-AD37-BCB9BC654435 wds:Q90990173-66FF9C78-B0D3-417D-AD39-14B04A083C76 wds:Q90990173-7AB19DD5-3A0B-4C75-88A4-90A6CB2AE09B wds:Q90990173-C193E51D-56AC-4AD8-96A7-4A842494C5BF wds:Q90990173-D2F02A0C-6F87-47B9-89B9-D7EC6825D7F6 wds:Q90990173-D6ECB923-F6C1-406B-9C4C-0C6EE7A2AE18
author	Rachel Schiff Antonio C. Wolff Anna Maria V. Storniolo Matthew P Goetz Susan Hilsenbeck Tao Wang
title	wds:Q90990173-C7B17EEE-1813-40D6-AFCC-2BF2BEA31CE8
title	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer (en)
page(s)	wds:Q90990173-E0F82C67-915B-48F8-B93D-2B28CF8F581C
page(s)	821-827
instance of	wds:Q90990173-86CD7C5F-E24A-496D-B808-9407D803CCB6
instance of	scholarly article
main subject	wds:Q90990173-77553A65-AC59-475B-8B43-371FA1C7F84F wds:Q90990173-B41106B2-18E5-4985-B619-A71B967BC51A
main subject	trastuzumab phase II clinical trial
PubMed ID	wds:Q90990173-FBDA01D2-9855-430D-81D2-B81A014EA5E8
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/31662331
PubMed ID	31662331
published in	wds:Q90990173-10B1711B-2228-46C6-B7FB-571F79609964
published in	Clinical Cancer Research
issue	wds:Q90990173-27488158-BEC9-4E3C-AF8F-9A8CDF6A6605
volume	wds:Q90990173-E9762AF3-C318-4DEF-98BF-7875E269156B
issue	4
volume	26
DOI	wds:Q90990173-4B0A8123-552F-4E4E-80FD-E98533B3EC15
DOI	http://dx.doi.org/10.1158/1078-0432.CCR-19-0851
DOI	10.1158/1078-0432.CCR-19-0851
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q90990173
is cites work of	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis Towards personalized treatment for early stage HER2-positive breast cancer An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06) HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
is cites work of	wds:Q92099708-34E6BA2F-F25D-4803-8E99-B9F2ACC4BD13 wds:Q89446547-1245F340-274E-4969-A4F5-A6A8944C12F4 wds:Q91974174-ABC7B9F2-1B48-490F-91FD-204E69A37464 wds:Q89471865-E522D53B-879A-4B81-9E19-B5893531460D

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software